PMID- 35569129
OWN - NLM
STAT- MEDLINE
DCOM- 20220808
LR  - 20221205
IS  - 1529-8019 (Electronic)
IS  - 1396-0296 (Linking)
VI  - 35
IP  - 8
DP  - 2022 Aug
TI  - A 24-weeks real-world experience of dupilumab in adolescents with 
      moderate-to-severe atopic dermatitis.
PG  - e15588
LID - 10.1111/dth.15588 [doi]
AB  - Dupilumab is a monoclonal antibody approved for the treatment of 
      moderate-to-severe atopic dermatitis (AD) in patients aged >/=12 years. Large, 
      double-blind, randomized, placebo-controlled trials showed its efficacy and 
      safety in adolescents. However, real-life data are few. The aim of this 
      monocentric retrospective observational study (December 2020-November 2021) was 
      to assess the effectiveness and safety of dupilumab in AD adolescents treated for 
      at least 24 weeks. For each patient demographic features, clinical data and 
      adverse events (AEs) were collected. Eczema Area and Severity Index (EASI), 
      Numerical Rating Scale (NRS) for pruritus (P-NRS) and for sleep disturbances 
      (S-NRS), and Children Dermatology Life Quality Index (cDLQI) were assessed at 
      baseline, week (W)4, W16, and W24. Twenty-seven patients (18 males; 
      15.23 +/- 3.54 years) were enrolled. Dupilumab was administered subcutaneously at 
      dosage of 600 mg induction dose, followed by 300 mg every 2 weeks in 14 (51.85%) 
      patients with a weight >/=60 kg, while 13 (48.15%) patients with a weight <60 kg 
      were treated with dupilumab 200 mg every 2 weeks after a loading dose of 400 mg. 
      The mean EASI score at baseline was 26.96 +/- 4.93 and significantly reduced to 
      3.74 +/- 3.47 at W16 (<0.001), and to 3.4 +/- 5.04 at W24 (p < 0.001). P-NRS 
      (9.14 +/- 0.94 at baseline vs. 2.33 +/- 4.93 at W16 [p < 0.001], and 1.45 +/- 2.35 at 
      W24 [p < 0.001]), S-NRS (7.88 +/- 1.64 at baseline vs. 0.92 +/- 1.35 at W16 
      [p < 0.001], and 1.66 +/- 2.84 at W24 [p < 0.0001]) and cDLQI (26.62 +/- 4.45 vs. 
      2.18 +/- 3.51 at baseline vs. 2.18 +/- 3.51 at W16 [p < 0.001], and 3.4 +/- 5.02 at W24 
      [p < 0.001]) showed a statistically significative improvement as well. 
      Injection-site reaction (5/27; 18.52%), conjunctivitis (2/27; 7.41%), and 
      asthenia (2/27; 7.41%) were the main AEs collected. This study seems to confirm 
      the efficacy and safety of dupilumab in adolescents with moderate-to-severe AD 
      also in real-life setting.
CI  - (c) 2022 Wiley Periodicals LLC.
FAU - Napolitano, Maddalena
AU  - Napolitano M
AUID- ORCID: 0000-0003-3309-8190
AD  - Department of Medicine and Health Sciences "Vincenzo Tiberio", University of 
      Molise, Campobasso, Italy.
FAU - Fabbrocini, Gabriella
AU  - Fabbrocini G
AUID- ORCID: 0000-0002-0064-1874
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Potestio, Luca
AU  - Potestio L
AUID- ORCID: 0000-0001-5940-0592
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Fontanella, Giuseppina
AU  - Fontanella G
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Picone, Vincenzo
AU  - Picone V
AUID- ORCID: 0000-0002-8137-8392
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Bennardo, Luigi
AU  - Bennardo L
AUID- ORCID: 0000-0002-0434-1027
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
FAU - Scalvenzi, Massimiliano
AU  - Scalvenzi M
AD  - Section of Dermatology - Department of Clinical Medicine and Surgery, University 
      of Naples Federico II, Naples, Italy.
FAU - Patruno, Cataldo
AU  - Patruno C
AD  - Department of Health Sciences, University Magna Graecia of Catanzaro, Catanzaro, 
      Italy.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Randomized Controlled Trial
DEP - 20220522
PL  - United States
TA  - Dermatol Ther
JT  - Dermatologic therapy
JID - 9700070
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 420K487FSG (dupilumab)
SB  - IM
MH  - Adolescent
MH  - Antibodies, Monoclonal, Humanized
MH  - Child
MH  - *Dermatitis, Atopic/diagnosis/drug therapy
MH  - Double-Blind Method
MH  - Humans
MH  - Injections, Subcutaneous
MH  - Male
MH  - Severity of Illness Index
MH  - Treatment Outcome
OTO - NOTNLM
OT  - adolescents
OT  - dupilumab
OT  - efficacy
OT  - real world
OT  - safety
EDAT- 2022/05/16 06:00
MHDA- 2022/08/09 06:00
CRDT- 2022/05/15 13:53
PHST- 2022/04/15 00:00 [revised]
PHST- 2021/12/12 00:00 [received]
PHST- 2022/05/13 00:00 [accepted]
PHST- 2022/05/16 06:00 [pubmed]
PHST- 2022/08/09 06:00 [medline]
PHST- 2022/05/15 13:53 [entrez]
AID - 10.1111/dth.15588 [doi]
PST - ppublish
SO  - Dermatol Ther. 2022 Aug;35(8):e15588. doi: 10.1111/dth.15588. Epub 2022 May 22.